Triple administration of osimertinib followed by chemotherapy for advanced lung adenocarcinoma: A case report

BACKGROUND: Osimertinib is the recommended first-line treatment for adult patients with epidermal growth factor receptor (EGFR) mutation positive advanced or metastatic non-small cell lung cancer (NSCLC). However, primary or acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) seems in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xu-Yan, Fei, Yu-Cheng, Zhou, Wen-Chao, Zhu, Jin-Miao, Lv, Dong-Lai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040179/
https://www.ncbi.nlm.nih.gov/pubmed/33889629
http://dx.doi.org/10.12998/wjcc.v9.i11.2627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040179/
https://www.ncbi.nlm.nih.gov/pubmed/33889629
http://dx.doi.org/10.12998/wjcc.v9.i11.2627

Ejemplares similares